Enigma Biomedical Group was founded to introduce a novel biotech-pharma model in Molecular Imaging and Medicine (MIM). The MIM concept unifies advanced diagnostics (such as PET/CT and near-infrared imaging, and gene/gene product analysis), with capabilities for state-of-the-art R&D for accelerated drug development and studying fundamental disease mechanisms. MIM is a multi-disciplinary philosophy, combining university and industry expertise, providing the environment for training, developing and deploying new technologies, and conducting clinical research. MIM provides a focal point for a paradigm shift from conventional medicine to “personalized medicine”.
Enigma Biomedical Group was founded to introduce a novel biotech-pharma model in Molecular Imaging and Medicine (MIM). The MIM concept unifies advanced diagnostics (such as PET/CT and near-infrared imaging, and gene/gene product analysis), with capabilities for state-of-the-art R&D for accelerated drug development and studying fundamental disease mechanisms. MIM is a multi-disciplinary philosophy, combining university and industry expertise, providing the environment for training, developing and deploying new technologies, and conducting clinical research. MIM provides a focal point for a paradigm shift from conventional medicine to “personalized medicine”.
- “Niche” radiopharmaceutical producer and distributor, with a network of Manufacturing and Distribution sites in the region.
- Development of new and proprietary tracers making them available to clinical service providers.
- CRO for traditional pharmaceutical companies to improve rates of drug discovery, and speed drug development and approval.
Toronto based Enigma Biomedical Group (EBG) partners with academic institutions and universities to foster and broaden access to novel research.
